Print Clear

MassHealth fallon health Health New England Where you matter. Mass General Brigham Health Plan TUFTS Health Plan WellSense HEALTH PLAN

Prior Authorization Request Administrative Information

Member information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race _____ Ethnicity _____

Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan contact information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, and Children's Medical Security Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Pharmacy Benefit Reviews): go.covermymeds.com/OptumRx Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555 Online Prior Authorization (Medical Specialty Reviews): provider.massgeneralbrighamhealthplan.org Medical Specialty Reviews: Fax: (888) 656-6671 - Tel: (833) 895-2611
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Antiemetics and Appetite Stimulants
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested

- ☐ Akynzeo (fosnetupitant/palonosetron injection) > 2 injections/28 days
- ☐ Akynzeo (netupitant/palonosetron capsule) > 2 units/28 days
- ☐ aprepitant 40 mg, 125 mg capsule > 2 units/28 days
- ☐ aprepitant 80 mg > 4 units/28 days
- ☐ aprepitant trifold pack > 2 packs/28 days
- ☐ Bonjesta (doxylamine/pyridoxine extended-release)
- ☐ Cinvanti (aprepitant injectable emulsion)
- ☐ doxylamine/pyridoxine delayed-release
- ☐ dronabinol > 2 units/day
- ☐ Emend (aprepitant powder for oral suspension) > 6 units/28 days
- ☐ Focinvez (fosaprepitant injection)
- ☐ fosaprepitant injection > 2 injections/28 day
- ☐ granisetron tablet > 2 units/28 days
- ☐ megestrol 625 mg/5 mL suspension
- ☐ ondansetron 16 mg orally disintegrating tablet
- ☐ ondansetron solution ≥ 13 years
- ☐ palonosetron 0.25 mg/2 mL injection > 2 injections/28 days
- ☐ palonosetron 0.25 mg/5 mL injection > 2 injections/28 days
- ☐ Sancuso (granisetron transdermal system)
- ☐ Sustol (granisetron extended-release injection)

Dose, frequency and duration of requested medication

Indication (Check all that apply or include ICD-10 code, if applicable.)

- ☐ AIDS-associated anorexia
- ☐ AIDS-associated cachexia
- ☐ AIDS-associated weight loss
- ☐ Chemotherapy-induced nausea and vomiting (CINV)
- ☐ Hyperemesis gravidarum
- ☐ Postoperative nausea and vomiting (PONV)
- ☐ Radiation-induced nausea and vomiting (RINV)
- ☐ Other

Section I. Please complete for Cinvanti requests.

Has the member had a trial of oral aprepitant or fosaprepitant injection?

☐ Yes. Please list the drug name, dates/duration of trial, and outcomes below.

Drug name Dates/duration of use

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

☐ No. Please explain why not.

Section II. Please complete for Akynzeo, aprepitant, dronabinol, Emend powder for oral suspension, fosaprepitant injection, and palonosetron requests exceeding the quantity limit.

Please describe the medical necessity for exceeding the quantity limit.

Section III. Please complete for ondansetron solution requests.

Does the member have a medical condition in which they are unable to swallow tablets/capsules?

☐ Yes. Please list reason.

☐ No. Please provide clinical rationale why conventional dosage forms cannot be used.

Section IV. Please complete for Sancuso requests.

Has the member had a trial of ondansetron ODT?

☐ Yes. Please list the dates/duration of trial and outcomes below.

Dates/duration of use

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

☐ No. Please explain why not.

Section V. Please complete for Bonjesta and doxylamine/pyridoxine delayed-release requests.

1. Has the member had a trial of pyridoxine?

   ☐ Yes. Please list the dates/duration of trial and outcomes below.

   Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

   Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

   ☐ No. Please explain why not.

2. Has the member had a trial of doxylamine?

   ☐ Yes. Please list the dates/duration of trial and outcomes below.

   Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

   Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

   ☐ No. Please explain why not.

3. For Bonjesta requests, has the member had a trial of doxylamine/pyridoxine delayed-release?

   ☐ Yes. Please list the dates/duration of trial and outcomes below.

   Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

over

Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

☐ No. Please explain why not.

Section VI. Please complete for Focinvez requests.

Please describe the clinical rationale for use of the requested agent instead of fosaprepitant injection (Emend).

Section VII. Please complete for ondansetron 16 mg ODT requests.

Please describe the clinical rationale for use of the requested agent instead of ondansetron ODT at an equivalent dose that is available without prior authorization.

Section VIII. Please complete for granisetron tablet requests exceeding the quantity limit.

1. Please describe the medical necessity for exceeding the quantity limit.
2. Has the member had a trial of ondansetron oral tablets or ondansetron ODT?
   ☐ Yes. Please list the dates/duration of trial and outcomes below.

   Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other

   Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

   ☐ No. Please explain why not.
3. Is the member on an anti-cancer treatment regimen that includes an oral agent? ☐ Yes ☐ No
4. Does the member require additional breakthrough treatment for CINV and is already on an antiemetic agent from a different therapeutic class? ☐ Yes ☐ No

   If yes, please list the additional antiemetic agent below.

Section IX. Please complete for megestrol 625 mg/5 mL suspension requests.

For initial requests, please attach medical records documenting an inadequate response or adverse reaction to one or a contraindication to both megestrol 40 mg/mL suspension and megestrol tablet.

For recertification requests, please provide response to therapy including weight gain or no net weight loss from baseline, or clinical rationale for continued therapy despite weight loss.

Section X. Please complete for Sustol requests.

1. Has the member had a trial of granisetron injection?
   ☐ Yes. Please list the dates/duration of trial and outcomes below.

   Dates/duration of use

over

Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other
Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

☐ No. Please explain why not.

2. Has the member had a trial of Sancuso?
   ☐ Yes. Please list the dates/duration of trial and outcomes below.
   Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other
   Briefly describe details of adverse reaction, inadequate response, contraindication, or other.

   ☐ No. Please explain why not.

Section XI. Please complete and provide documentation for exceptions to step therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to, the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
   ☐ Yes ☐ No
   If yes, please provide details for the previous trial.
   Drug name Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the healthcare provider, and switching drugs will likely cause an adverse reaction in, or physical or mental harm to, the member?
   ☐ Yes. Please provide details.
   ☐ No

Please continue to next page and complete Prescriber and Provider Information section.

over

Prior Authorization Request Prescriber and Provider Information

Prescriber information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

E-mail address

Telephone No.*

Fax No.* (Please provide fax number for PA response notification.)

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am either the prescribing provider or duly authorized to act on behalf of the provider identified in the Prescriber information section of this form. Any attached statement on letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Signature of provider or individual duly authorized to act on behalf of the provider:

Printed legal name and title of signatory above

Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)